Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability
Janssen Has First Combo Data, With Its Own Darzalex
Executive Summary
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.
You may also be interested in...
J&J Advances Myeloma Domination Plan With Bispecific Tecvayli Approval
With Darzalex and Carvykti already making J&J a leader in the field, the company has added another dimension to its offering with the first multiple myeloma bispecific antibody therapy.
As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus
Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.
Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half
Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.